A phase 2 trial of single-agent amrubicin in patients with extensive disease small cell lung cancer that is refractory or progressive within 90 days of completion of first line platinum-based chemotherapy

Trial Profile

A phase 2 trial of single-agent amrubicin in patients with extensive disease small cell lung cancer that is refractory or progressive within 90 days of completion of first line platinum-based chemotherapy

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Aug 2017

At a glance

  • Drugs Amrubicin (Primary)
  • Indications Small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Cabrellis Pharmaceuticals; Celgene Corporation; Pharmion Corporation
  • Most Recent Events

    • 05 Aug 2009 Results were presented at the 13th World Conference on Lung Cancer, according to a Celgene Corporation media release.
    • 02 Jun 2009 Primary endpoint 'Objective clinical response rate' has been met; results presented at ASCO 2009.
    • 08 Apr 2009 Actual end date added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top